Headlines about Alphatec (NASDAQ:ATEC) have trended somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alphatec earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave news stories about the medical technology company an impact score of 46.4505609600907 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
ATEC has been the subject of several research reports. ValuEngine downgraded Alphatec from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Lake Street Capital initiated coverage on Alphatec in a report on Monday, October 16th. They issued a “buy” rating and a $7.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Alphatec in a report on Wednesday, November 22nd.
Alphatec (NASDAQ:ATEC) traded up $0.41 during trading on Tuesday, hitting $3.41. The stock had a trading volume of 468,700 shares, compared to its average volume of 207,660. The company has a debt-to-equity ratio of -1.11, a current ratio of 2.11 and a quick ratio of 1.08. The stock has a market cap of $57.20, a P/E ratio of -1.55 and a beta of 1.35. Alphatec has a fifty-two week low of $1.58 and a fifty-two week high of $5.80.
Alphatec Holdings, Inc is a medical technology company. The Company through its subsidiary, Alphatec Spine, Inc and its subsidiaries, designs, develops, manufactures and markets products for the surgical treatment of spine disorders. Its product portfolio and pipeline addresses the cervical, thoracolumbar and intervertebral regions of the spine and covers a range of spinal disorders and surgical procedures.
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.